Digostics has initiated a pivotal university trial in partnership with Yale School of Medicine to evaluate the GTT@home Oral Glucose Tolerance Test (OGTT) for at-home use in diagnosing and monitoring early-stage type 1 diabetes (T1D). Funded by Breakthrough T1D, the global research and advocacy organization, the study seeks to validate the accuracy, reproducibility, and user acceptance of GTT@home when compared to traditional, clinic-based OGTTs. The trial marks a significant step forward in diabetes care, aiming to remove barriers that prevent many individuals-especially children and high-risk individuals—from undergoing timely diagnostic testing.

The GTT@home device enables patients to perform a glucose tolerance test using just finger-prick blood samples and a preformulated glucose drink, all from the convenience of their own home. This approach eliminates the need for invasive intravenous lines, long clinic visits, and early-morning hospital appointments. By simplifying the process and making it more accessible, GTT@home has the potential to support more frequent monitoring, especially for those already identified as being at risk due to the presence of T1D autoantibodies. The test has already demonstrated its clinical utility in gestational and type 2 diabetes, and its application in T1D could broaden the scope of early detection.

As new therapies emerge that can delay or prevent the onset of type 1 diabetes, tools like GTT@home are essential to facilitate early staging and intervention. The ongoing study at Yale will help determine the clinical readiness of this at-home solution and inform future regulatory pathways in the U.S. With existing approvals in Europe and the UK for other diabetes types, GTT@home is poised to become a transformative tool in diabetes diagnostics—enabling personalized, accessible, and proactive disease management for at-risk individuals worldwide.